ATE316966T1 - Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente - Google Patents

Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente

Info

Publication number
ATE316966T1
ATE316966T1 AT03712152T AT03712152T ATE316966T1 AT E316966 T1 ATE316966 T1 AT E316966T1 AT 03712152 T AT03712152 T AT 03712152T AT 03712152 T AT03712152 T AT 03712152T AT E316966 T1 ATE316966 T1 AT E316966T1
Authority
AT
Austria
Prior art keywords
medications
production
benzoxazinone derivatives
benzoxazinone
derivatives
Prior art date
Application number
AT03712152T
Other languages
English (en)
Inventor
Antonio Torrens-Jover
Jose Aurelio Castrillo-Perez
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE316966T1 publication Critical patent/ATE316966T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03712152T 2002-04-09 2003-04-09 Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente ATE316966T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
ATE316966T1 true ATE316966T1 (de) 2006-02-15

Family

ID=28686085

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03718741T ATE489382T1 (de) 2002-04-09 2003-04-08 Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
AT03712152T ATE316966T1 (de) 2002-04-09 2003-04-09 Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03718741T ATE489382T1 (de) 2002-04-09 2003-04-08 Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel

Country Status (28)

Country Link
US (3) US7056914B2 (de)
EP (2) EP1497285B1 (de)
JP (1) JP2005529866A (de)
KR (1) KR20050008679A (de)
CN (1) CN1659164A (de)
AR (2) AR039256A1 (de)
AT (2) ATE489382T1 (de)
AU (2) AU2003222804A1 (de)
BR (1) BR0309083A (de)
CA (1) CA2481701A1 (de)
DE (2) DE60335094D1 (de)
DK (1) DK1500654T3 (de)
EC (1) ECSP045353A (de)
ES (3) ES2193875B2 (de)
HR (1) HRP20040919A2 (de)
IL (1) IL164442A0 (de)
IS (1) IS7491A (de)
MA (1) MA27692A1 (de)
MX (1) MXPA04009889A (de)
NO (1) NO20044322L (de)
NZ (1) NZ536167A (de)
PL (1) PL372537A1 (de)
PT (1) PT1500654E (de)
RU (1) RU2004133041A (de)
TN (1) TNSN04203A1 (de)
UA (1) UA79460C2 (de)
WO (2) WO2003084952A1 (de)
ZA (1) ZA200408275B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン－１－カルボキサミド誘導体
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
CA2590433C (en) * 2005-03-21 2012-09-18 The Procter & Gamble Company Multi-phase personal care composition comprising visually distinct phases
MX2007012898A (es) * 2005-04-13 2007-12-10 Procter & Gamble Composicion de fases multiples estructurada para el cuidado personal que comprende surfactantes anionicos ramificados.
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101326106A (zh) * 2005-12-08 2008-12-17 宝洁公司 包括邻近表面形貌定位的模内标签的容器
CA2632508A1 (en) * 2005-12-28 2008-06-05 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
EP2061795B1 (de) * 2006-08-14 2014-01-15 Council of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepinhybride und verfahren zu ihrer herstellung
EP1902733A1 (de) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Kombination von einem NMDA Rezeptorligand und einer Verbindung mit 5-HT6 Rezeptor-Affinität
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
WO1995028397A1 (en) 1994-04-14 1995-10-26 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
CA2273102A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Urea derivatives
EP0910565A1 (de) 1997-02-14 1999-04-28 Bayer Corporation Amidderivate als selektive neuropeptid-y-rezeptoren
WO1998040356A1 (en) 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2002526521A (ja) 1998-10-07 2002-08-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経ペプチドｙのｙ５受容体のリガンドとしてのｎ−アラルキルアミノテトラリン
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
ATE427935T1 (de) * 2001-08-07 2009-04-15 Banyu Pharma Co Ltd Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
IL164442A0 (en) 2005-12-18
HRP20040919A2 (en) 2005-04-30
EP1500654B1 (de) 2006-02-01
ES2193875B2 (es) 2005-03-01
EP1500654A1 (de) 2005-01-26
ES2193875A1 (es) 2003-11-01
CN1659164A (zh) 2005-08-24
WO2003084952A1 (en) 2003-10-16
NZ536167A (en) 2006-06-30
ATE489382T1 (de) 2010-12-15
MXPA04009889A (es) 2005-08-16
EP1497285B1 (de) 2010-11-24
IS7491A (is) 2004-10-06
JP2005529866A (ja) 2005-10-06
US7514429B2 (en) 2009-04-07
US20040067941A1 (en) 2004-04-08
DK1500654T3 (da) 2006-06-06
KR20050008679A (ko) 2005-01-21
US7041665B2 (en) 2006-05-09
ZA200408275B (en) 2006-04-26
MA27692A1 (fr) 2006-01-02
PL372537A1 (en) 2005-07-25
ES2356815T3 (es) 2011-04-13
HK1069820A1 (en) 2005-06-03
AR048567A1 (es) 2006-05-10
RU2004133041A (ru) 2005-09-10
UA79460C2 (en) 2007-06-25
TNSN04203A1 (en) 2007-03-12
AU2003222804A1 (en) 2003-10-20
CA2481701A1 (en) 2003-10-16
PT1500654E (pt) 2006-06-30
WO2003084939A1 (es) 2003-10-16
NO20044322L (no) 2004-10-12
AU2003216934A1 (en) 2003-10-20
DE60335094D1 (de) 2011-01-05
DE60303440T2 (de) 2006-10-26
ECSP045353A (es) 2005-01-28
US20060128701A1 (en) 2006-06-15
US20040058920A1 (en) 2004-03-25
EP1497285A1 (de) 2005-01-19
BR0309083A (pt) 2005-04-19
ES2258219T3 (es) 2006-08-16
US7056914B2 (en) 2006-06-06
AR039256A1 (es) 2005-02-16
DE60303440D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
ATE316966T1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE469152T1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE353900T1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE602005006815D1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE430150T1 (de) 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
ATE409184T1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE524178T1 (de) Acylierte, heteroaryl-kondensierte cycloalkenylamine und deren verwendung als arzneimittel
ATE420072T1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE336491T1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE357448T1 (de) Benzoxazinonderivative, deren herstellung und verwendung
ATE412635T1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE403649T1 (de) Neue imidazolderivative, deren herstellung und deren verwendung als medikament
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE602005019743D1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE484503T1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
ATE451366T1 (de) Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1500654

Country of ref document: EP

REN Ceased due to non-payment of the annual fee